Citations

Showing 10 of 108094 citations.

Iopofosine I-131 treatment in late line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
Lngcor, Jarrod, Callander, Natalie S. , Oliver, Kate , Chanan‐Khan, Asher , Ailawadhi, Sikander , Ailawadhi, Sikander , Callander, Natalie , Oliver, Kate

Mayo Clinic

No container title available | August 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1751276/v1 Get It

Abstract Over the past decade, significant improvements in survival outcomes have been experienced by multiple myeloma (MM) patients. However, MM remains an incurable disease and patients with triple-class refractory MM have limited treatment options and a dismal prognosis. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has transformed the treatment algorithm of relapsed/refractory MM (RRMM), with high overall response rates. Nevertheless, a significant proportion of patients ultimately relapse despite achieving deep remission and show poor outcomes with subsequent treatment post anti-BCMA immunotherapies.1 Iopofosine I-131 (iopofosine) is a first-in-class phospholipid ether radio-conjugate that targets lipid raft microdomains on tumor cells and is internalized. Here we present seven cases of triple class refractory MM patients that relapsed or were refractory to anti-BCMA immunotherapy and treated with iopofosine plus low dose dexamethasone (LoDEX). Patient received a single fractionated cycle of 30mCi/m2 of iopofosine (15 mg/m2 dosed day 1 and day 15) and received LoDEX (40 mg/week for 12 weeks) with an optional second cycle of iopofosine approximately 60 days later. Six of the seven patients achieved the minimum required total administered dose of 60 millicuries (mCi) to be in the evaluable population and 50% achieved a partial response (PR) or better.
Unusual Cause of Persistent Epistaxis with Severe Anemia in a Child
Zemene, Yilkal , Hailu, Tadele , Wiedermann, Josh

Mayo Clinic

Case Reports in Otolaryngology | August 8, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-3

10.1155/2022/8557755 | PMID 35978608 Get It

Epistaxis in children can be caused by different systemic and local pathologies. Respiratory infections, nasal mucosa dryness, and foreign bodies are some local causes of bleeding from the nose. In developing countries, infestations still contribute a significant proportion of anemia in children. But it is very unusual for leech-causing persistent epistaxis with a consequence of severe anemia. We herein report a rare cause of severe anemia in a 5-year-old child presented to our clinic for persistent epistaxis. A leech was taken out with forceps, and his anemia was treated accordingly.
Dropped Gallstone-related Abscess
Beighton, Ryan, O'Hair, Marissa

Mayo Clinic

No container title available | August 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1148/cases.20227645 Get It

Longitudinal Evolution of Cardiac Dysfunction in Heart Failure and Preserved Ejection Fraction With Normal Natriuretic Peptide Levels
Sorimachi, Hidemi, Verbrugge, Frederik H. , Omote, Kazunori , Obokata, Masaru , Reddy, Yogesh N.V. , Ye, Zi , Michelena, Héctor I. , Borlaug, Barry A. , Omar, Massar , Obokata, Masaru , Michelena, Hector I , Borlaug, Barry A , Nishimura, Rick , Verbrugge, Frederik H , Omar, Massar

Mayo Clinic

Circulation | August 8, 2022 | Volume: 146 | Issue: 6 | Pages: 500-502

10.1161/circulationaha.121.058592 | PMID 35939545 Get It

Measuring Health-Related Quality of Life in Thyroid Eye Disease
Sharma, Anu , Stan, Marius N. , Rootman, Dan B. , Stan, Marius N

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | August 8, 2022 | Volume: 107 | Issue: Supplement_1 | Pages: S27-S35

10.1210/clinem/dgac230 | PMID 36346683 Get It

Abstract Health-related quality of life (HQOL) is a concept that aims to understand the totality of an individual’s experience of their disease state. This can include the physical, psychosocial, emotional, and psychological effects of a disease state. A complex and multifactorial concept, HQOL can be challenging to measure accurately and reliably. Thyroid eye disease (TED), as a multifaceted physically debilitating and facial disfiguring disorder, presents unique challenges and opportunities in the measurement of HQOL. Multiple distinct tools have been developed for this purpose, each has been constructed, assessed, and utilized. This discussion surveys the landscape of TED-related QOL measurement and presents challenges for the future. Clinicians and clinical researchers should implement TED-related QOL measurement as part of routine TED care and as a primary outcome in TED clinical trials. We recommend utilizing the Graves’ ophthalmopathy (GO)-QOL routinely in clinical practice and as a primary outcome in TED clinical trials. If the GO-QOL is too time-consuming or in mild TED, a faster alternative is the TED-QOL.
Treatment of Clostridioides difficile Infection
Sehgal, Kanika , Cifu, Adam S. , Khanna, Sahil

Mayo Clinic

JAMA | August 8, 2022 | Volume: 328 | Issue: 9 | Pages: 881

10.1001/jama.2022.12251 | PMID 35939317 Get It

Adherence to continuous positive airway pressure reduces the risk of 30-day hospital readmission among older adults with comorbid obstructive sleep apnea and cardiovascular disease
Albrecht, Jennifer S. , Bailey, M. Doyinsola , Wickwire, Emerson M. , Somers, Virend K.

Mayo Clinic

Journal of Clinical Sleep Medicine | August 8, 2022 | Volume: 18 | Issue: 12 | Pages: 2739-2744

10.5664/jcsm.10196 | PMID 35934923 Get It

Pre S cription Digita L Th E rap E utic for P
Dreyer, Rachel P. , Berkowitz, Alyssa, Schneeberg, Lynelle, Shah, Nilay D. , Emanuel, Lindsay, Kolla, Bhanuprakash , Jeffery, Molly M. , Deeg, Mark A. , Ervin, Keondae, Thorndike, Frances P. , Jeffery, Molly Moore , Yaggi, Henry Klar , Kolla, Bhanu Prakash , Ross, Joseph S.

Mayo Clinic

BMJ Open | August 8, 2022 | Volume: 12 | Issue: 8 | Pages: e062041

10.1136/bmjopen-2022-062041 | PMID 35940841 Get It

Introduction Cognitive behavioural therapy for insomnia (CBT-I) is effective at treating chronic insomnia, yet in-person CBT-I can often be challenging to access. Prior studies have used technology to bridge barriers but have been unable to extensively assess the impact of the digital therapeutic on real-world patient experience and multidimensional outcomes. Among patients with insomnia, our aim is to determine the impact of a prescription digital therapeutic (PDT) (PEAR-003b, FDA-authorised as Somryst; herein called PDT) that provides mobile-delivered CBT-I on patient-reported outcomes (PROs) and healthcare utilisation. Methods and analysis We are conducting a pragmatically designed, prospective, multicentre randomised controlled trial that leverages Hugo, a unique patient-centred health data-aggregating platform for data collection and patient follow-up from Hugo Health. A total of 100 participants with insomnia from two health centres will be enrolled onto the Hugo Health platform, provided with a linked Fitbit (Inspire 2) to track activity and then randomised 1:1 to receive (or not) the PDT for mobile-delivered CBT-I (Somryst). The primary outcome is a change in the insomnia severity index score from baseline to 9-week postrandomisation. Secondary outcomes include healthcare utilisation, health utility scores and clinical outcomes; change in sleep outcomes as measured with sleep diaries and a change in individual PROs including depressive symptoms, daytime sleepiness, health status, stress and anxiety. For those allocated to the PDT, we will also assess engagement with the PDT. Ethics and dissemination The Institutional Review Boards at Yale University and the Mayo Clinic have approved the trial protocol. This trial will provide important data to patients, clinicians and policymakers about the impact of the PDT device delivering CBT-I on PROs, clinical outcomes and healthcare utilisation. Findings will be disseminated to participants, presented at professional meetings and published in peer-reviewed journals. Trial registration number NCT04909229 .
Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance
Jevremović, Dragan , Nanaa, Ahmad , Geyer, Susan M. , Timm, Michael, Azouz, Haya , Hengel, Cynthia, Reberg, Alexander, He, Rong , Viswanatha, David S., Salama, Mohamad E., Olteanu, Horatiu , Otteson, Gregory E., Greipp, Patricia T. , Xie, Zhuoer , Litzow, Mark R. , Patnaik, Mrinal M. , Al‐Kali, Aref , Nguyen, Phuong L., Viswanatha, David, Shi, Min , Olteanu, Horatiu , Horna, Pedro , Otteson, Gregory, Jevremovic, Dragan , Xie, Zhuoer , Greipp, Patricia T , Alkhateeb, Hassan B. , Hogan, William J. , Shah, Meera

Mayo Clinic

American Journal of Clinical Pathology | August 8, 2022 | Volume: 158 | Issue: 4 | Pages: 530-536

10.1093/ajcp/aqac083 | PMID 35938646 Get It

Abstract Objectives Patients with clonal cytopenia of undetermined significance (CCUS) are at increased risk of developing myeloid neoplasia (MN). We evaluated whether a simple flow cytometry immunophenotyping (FCIP) assay could differentiate the risk of development of MN in patients with CCUS. Methods Bone marrow aspirates were assessed by FCIP panel in a cohort of 80 patients identified as having CCUS based on next-generation sequencing or cytogenetics from March 2015 to May 2020, with available samples. Flow cytometric assay included CD13/HLA-DR expression pattern on CD34-positive myeloblasts; CD13/CD16 pattern on maturing granulocytic precursors; and aberrant expression of CD2, CD7, or CD56 on CD34-positive myeloblasts. Relevant demographic, comorbidity, and clinical and laboratory data, including the type and extent of genetic abnormalities, were extracted from the electronic health record. Results In total, 17 (21%) patients with CCUS developed MN over the follow-up period (median survival follow-up, 28 months [95% confidence interval, 19-31]). Flow cytometry immunophenotyping abnormalities, including the aberrant pattern of CD13/HLA-DR expression, as detected at the time of the diagnosis of CCUS, were significantly associated with risk of developing MN (hazard ratio, 2.97; P = .006). Additional FCIP parameters associated with the development of MN included abnormal expression of CD7 on myeloblasts and the presence vs absence of any FCIP abnormality. Conclusions A simple FCIP approach that includes assessment of CD13/HLA-DR pattern on CD34-positive myeloblasts can be useful in identifying patients with CCUS at higher risk of developing MN.
Resolution of severe cardiomyopathy after catheter ablation of an anteroseptal accessory pathway: A case report
Baqal, Omar , Ladia, Vatsal, Masry, Hicham El , Baqal, Omar J , El Masry, Hicham

Mayo Clinic

Annals of Noninvasive Electrocardiology | August 8, 2022 | Volume: 28 | Issue: 2 | Pages: No page available

10.1111/anec.13001 | PMID 35938621 Get It

AbstractIn patients with non‐sustained tachyarrhythmias, left ventricular (LV) systolic dysfunction is uncommon. The role of catheter ablation (CA) in asymptomatic patients with tachyarrhythmia remains unclear. We report a 20‐year‐old patient without sustained tachyarrhythmia with a left ventricular ejection fraction of 20% who underwent radiofrequency catheter ablation (RFCA) of anteroseptal accessory pathway. She achieved normalization of left ventricular systolic function noted on echocardiography performed at 4 weeks post‐ablation. Our case highlights significant improvement in LV systolic function after catheter ablation of an “asymptomatic” ventricular pre‐excitation. Current guidelines do not endorse ablating asymptomatic patients, but careful follow‐up with serial echocardiograms might be warranted. Prophylactic ablation of those patients with clear evidence of LV dyssynchrony or wide left bundle branch pattern and persistent pre‐excitation is worth further consideration.